Heliyon
Volume 9, Issue 4, April 2023, e15032
Journal home page for Heliyon

Research article
Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus

https://doi.org/10.1016/j.heliyon.2023.e15032Get rights and content
Under a Creative Commons license
open access

Highlights

  • · Identification of well characterized antibodies that bind to SARS-CoV-1 but not to SARS-CoV-2.

  • The use of RosettaAntibodyDesign to design variants of the anti-SARS-CoV-1 antibodies bind to SARS-CoV-2 with high affinity.

  • Experimental validation of the antibodies designed in silico.

Abstract

The human infectious disease COVID-19 caused by the SARS-CoV-2 virus has become a major threat to global public health. Developing a vaccine is the preferred prophylactic response to epidemics and pandemics. However, for individuals who have contracted the disease, the rapid design of antibodies that can target the SARS-CoV-2 virus fulfils a critical need. Further, discovering antibodies that bind multiple variants of SARS-CoV-2 can aid in the development of rapid antigen tests (RATs) which are critical for the identification and isolation of individuals currently carrying COVID-19. Here we provide a proof-of-concept study for the computational design of high-affinity antibodies that bind to multiple variants of the SARS-CoV-2 spike protein using RosettaAntibodyDesign (RAbD). Well characterized antibodies that bind with high affinity to the SARS-CoV-1 (but not SARS-CoV-2) spike protein were used as templates and re-designed to bind the SARS-CoV-2 spike protein with high affinity, resulting in a specificity switch. A panel of designed antibodies were experimentally validated. One design bound to a broad range of variants of concern including the Omicron, Delta, Wuhan, and South African spike protein variants.

Keywords

Protein engineering
Coronavirus Disease 2019
Computational antibody design
Monoclonal antibody therapeutics
Diagnostic

Cited by (0)

1

Equal contribution.